Durable response to afatinib in advanced lung adenocarcinoma harboring a novel NPTN-NRG1 fusion: a case report

NRG1 fusions are rare oncogenic drivers in solid tumors, and the incidence of NRG1 fusions in non-small cell lung cancer (NSCLC) was 0.26%. It is essential to explore potential therapeutic strategies and effic...

Source: World Journal of Surgical Oncology - August 16, 2023 Category: Cancer & Oncology Authors: Xin Nie, Ping Zhang, Zhixin Bie, Chenhui Song, Min Zhang, Di Ma, Di Cui, Gang Cheng, Hui Li, Yan Lei, Xiaoxing Su, Wendy Wu and Lin Li Tags: Case Report Source Type: research